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health care services increased from $725,019,395 (mean
= $395; 95% CL = $140–$650) to $3,049,290,075 (mean
= $1,802; 95% CL = $618–$2,987). Total prescription
medication expenditures increased from $941,406,990
(mean = $24; 95% CL = $18–$29) to $1,202,568,785
(mean = $34; 95% CL = $30–$37). Expenditures on
ofﬁce-based medical provider and emergency department
visits showed minor increases while those on outpatient
services exhibited a minor decrease. CONCLUSIONS:
From 1996 to 1999, there was no difference in the preva-
lence of back pain however there was an $11.1 billion
increase in direct costs. Inpatient stays, home care ser-
vices, and prescription medications accounted for the
majority of this increase.
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OBJECTIVES: Gabapentin and topical lidocaine patch
(LIDO) are US FDA approved drugs for treatment of 
postherpetic neuralgia (PHN); tricyclics and opioids are
also frequently used. The cost-effectiveness of drug
therapy (Rx) for PHN is unclear. METHODS: We devel-
oped a Markov decision model to estimate the incremen-
tal cost-effectiveness of 5 management strategies for
established PHN in 70 year olds: no therapy, gabapentin,
LIDO, tricyclic (nortriptyline), or opiod (long acting mor-
phine). The analysis took a societal perspective, using 
reference case recommendations of the Panel on Cost-
Effectiveness in Health and Medicine. We used literature
data for parameter values, assuming that Rx related pain
relief equaled decreased PHN disutility. We also assumed
that gabapentin, nortriptyline, and opiod had identical
side effect likelihood (30%) and severity (possible bias
against gabapentin). One-way and multiway sensitivity
analyses were performed. RESULTS: In the baseline
analysis, nortriptyline is eliminated by extended domi-
nance. Compared to no treatment, opioid costs $60,000
per quality adjusted life year (QALY) gained. Compared
to opioid, gabapentin costs $74,000/QALY. Compared to
gabapentin, LIDO costs $795,000/QALY. In sensitivity
analyses, LIDO is preferred (<$75K/QALY) if pain relief
was >31% (baseline 23.8%) or if only 1 patch is required
(baseline 2). Opiod is not preferred if disutility due to
stigma is associated with its use but is preferred if pain
relief is >33% (base 32.3%). Nortriptyline is preferred if
pain relief is >22.5% (base 19.0%). Gabapentin domi-
nates all other Rx if its side effect frequency is <28%.
Monte Carlo analysis, with variation of all sensitive para-
meters over clinically plausible ranges, conﬁrms greater
economic acceptability of gabapentin. CONCLUSIONS:
In an analysis biased against its use, gabapentin is the
most economically reasonable choice for drug therapy of
established postherpetic neuralgia.
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OBJECTIVE: There is a lack of updated information on
healthcare expenditures and expenditure patterns for
individuals with back pain in the US. The objective of this
study is to use a recently released national survey data-
base to estimate total healthcare expenditures incurred 
by individuals with back pain in the US, calculate the
incremental expenditures attributable to back pain
among these individuals, and describe healthcare expen-
diture patterns of individuals with back pain.
METHODS: This study used data from 1998 Medical
Expenditure Panel Survey (MEPS), a national survey on
healthcare utilization and expenditures. Total healthcare
expenditures and per-capita expenditures among individ-
uals with back pain were calculated. Multivariate regres-
sion models were used to estimate the incremental
expenditures attributable to back pain. The expenditure
patterns were examined by stratifying individuals with
back pain by socio-demographic characteristics and
medical diagnosis, and calculating per-capita expendi-
tures for each stratiﬁed category. RESULTS: In 1998,
total healthcare expenditures incurred by individuals with
back pain in the US reached $90.7 billion and total incre-
mental expenditures attributable to back pain among
these persons were approximately $26.3 billion. On
average, individuals with back pain incurred expenditures
about 60% higher than individuals without back pain
($3495 vs. 2178). Among back pain individuals, at least
75% of service expenditures were attributed to those with
top 25% expenditure and per-capita expenditures were
generally higher for those who were older, female, whites,
medically insured or suffered from disc disorders. CON-
CLUSIONS: Healthcare expenditures for back pain in the
US in 1998 were substantial. The expenditures demon-
strated wide variations among individuals with different
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OBJECTIVE: To compare the drug utilization patterns,
in particular the compliance and persistency of therapy,
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between donepezil and rivastigmine; two cholinesterase
inhibitors used for the symptomatic treatment of patients
with Alzheimer’s disease (AD). METHODS: This retro-
spective database analysis, utilizing data from a national
Pharmacy Beneﬁt Management company, considered 
prescription claims data collected from January 1, 2000
through March 31, 2002. All patients had no previous
evidence of AD treatment for six months prior to the
index date (deﬁned as the date of the ﬁrst prescription for
either donepezil or rivastigmine), and all patients were
followed for nine months post-index date. Donepezil and
rivastigmine patients were required to have at least one
prescription of either donepezil or rivastigmine treatment.
RESULTS: Data from 6635 patients were analyzed. The
donepezil population comprised 6071 patients with a
mean age of 77.8 years, and the rivastigmine population
comprised 564 patients with a mean age of 78.0 years.
There was no signiﬁcant difference in the gender distrib-
ution between the donepezil and rivastigmine groups. The
mean duration of therapy was 170.3 days for donepezil
patients, compared with 75.2 days for rivastigmine
patients (P < 0.001). Furthermore, 60% of rivastigmine
patients discontinued therapy in the ﬁrst 31 days of treat-
ment, compared with 20% of donepezil patients in the
same treatment period (P < 0.0001). At the end of the 
9-month study, more donepezil patients remained on
therapy (38%) than rivastigmine patients (8%) (P <
0.0001). CONCLUSION: The majority of rivastigmine
patients discontinued treatment within one month, while
over one-third of donepezil patients remained on therapy
for at least nine months. This study suggests that patients
are better able to maintain persistent treatment with
donepezil than rivastigmine.
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OBJECTIVE: The objective of this analysis was to 
evaluate the psychometric properties of the 24 Hour
Headache Disability Questionnaire (Disq-24) using con-
ﬁrmatory factor analysis. Disq24 is a 14-item question-
naire with a 6-point Likert-type scale that measures
disability in the 24 hours following onset of headache
pain. METHODS: We utilized data from an acute
migraine treatment clinical trial in which the Disq-24 was
administered 24-hours after onset of headache pain (N =
323). The Disq24 was originally hypothesized to measure
the impact of headache on Family/Social Activities, Work
Activities and Emotions/Feelings. It is uncertain whether
the Family/Social/Work Activities domain should be com-
bined to a single factor. We tested the hypotheses by esti-
mating 2-factor and 3-factor conﬁrmatory factor-analytic
models using maximum likelihood ﬁtting function in
AMOS Version 4.0. To assess data ﬁt, we used the chi-
square test and ﬁt indices including Tucker-Lewis Index
(TLI), Incremental Fit Index (IFI) and Root Mean Square
Error of Approximation (RMSEA). RESULTS: The chi-
square statistic indicated that the 2-factor model had a
poor ﬁt. (p = 0.000). However given the sensitivity of this
test to sample size, the other ﬁt indices TLI (0.923), IFI
(0.936) and RMSEA (0.107) indicated a reasonably good
ﬁt. Item 8 (0.434) and Item 10 (0.449) had low squared
multiple correlations, indicating only a small proportion
of variance in these items was explained by this model.
Data ﬁt improved marginally in the 3-factor model but
correlation between the Work and Social Factor was
0.943 indicating that both were driven by a single factor.
Deleting Items 8 and 10 resulted in a model with TLI
(0.947), IFI (0.958) and RMSEA (0.098) indicating a sig-
niﬁcant improvement in ﬁt. CONCLUSIONS: Results
from CFA suggested better data ﬁt with a 2-factor struc-
ture. The psychometric properties of the instrument can
be improved by revising/deleting Items 8 and 10.
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OBJECTIVES: Understanding rating scale properties is
essential in using instruments to determine clinically
important differences associated with disease treatments
and determining their value. This study seeks to deter-
mine whether the Behavior Pathology in Alzheimer’s
Disease Frequency Weighted Severity Scale (BEHAVE-
AD-FW) measures symptoms of dementia distinct from
cognitive function. METHODS: Baseline data on 215
outpatients with probable AD in a randomized, double-
blind, placebo-controlled clinical trial. Higher scores on
the BEHAVE-AD-FW total score and category scores
(paranoid/delusions; hallucinations; activity disturbance;
aggression; diurnal rhythm variation; affective distur-
bance; anxieties/phobia) indicate more pathological
behavior. Pearson correlations were used to correlate the
BEHAVE-AD-FW (total score and category scores) with
cognitive function as measured by the Alzheimer’s Disease
Assessment Scale—cognitive subscale (ADAS-cog) and
Mini Mental State Exam (MMSE). RESULTS: Mean age
was 75.12 years and the percentage female was 57.94%.
At baseline, the mean (standard deviation, sd) scores of
cognitive function reﬂected a population with mild AD:
ADAS-cog, 21.88 (8.65;), MMSE, 19.77 (3.67). The
BEHAVE-AD-FW total score range was 0 to 25; its mean
(sd) and median were 4.10 (4.68) and 3. Seven sub-scales
of BEHAVE-AD-FW display signiﬁcant levels of symp-
toms (p < 0.005). Although statistically signiﬁcant and in
the expected direction, the magnitude of the correlations
of the total score of the BEHAVE-AD-FW with ADAS-
Cog (r = 0.22) and MMSE (r = -0.19), was relatively low.
